TY  - JOUR
AU  - HU Yu-rong
AU  - QIAO Hai-ling
AU  - KAN Quan-cheng
PY  - 2016
TI  - Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes
JF  - Acta Pharmacologica Sinica; Vol 25, No 8 (August 2004): Acta Pharmacologica Sinica
Y2  - 2016
KW  - 
N2  - AIM:  To study the kinetic characteristics of lansoprazole in healthy Chinese subjects in relation to CYP2C19 genotype status for the individualized dose regimen of lansoprazole.  METHODS:  Nine homozygous extensive metabolizers (homo EMs) and 9 poor metabolizers (PMs) were recruited for the study from a total of 70 healthy Chinese volunteers, whose CYP2C19 genotype status was determined by the PCR-RFLP techniques. After a single oral dose of 30 mg lansoprazole capsule, plasma concentrations of lansoprazole were determined with HPLC method.  RESULTS:  In Chinese subjects, the allele frequencies of the CYP2C19m1 and CYP2C19m2 mutation were 0.35 and 0.07, respectively. The concentration-time curves in the two groups were best fitted to a one-compartment model. In the homo EMs and the PMs groups, the main kinetic parameters were as follows: Tmax (2.44+/-0.85) and (2.33+/-0.94) h, Cmax(1.10+/-0.34) and (1.73+/-0.56) mg/L, Cl/F (16.55+/-0.38) and (3.58+/-1) L/h, T1/2ke (1.96+/-0.51) and (4.21+/-0.53) h, AUC were (3.23+/-0.08) and (11.05+/-0.23) mg.L(-1). A significant difference in AUC, T1/2ke, Cl/F, Cmax values existed between the two groups (P
UR  - http://www.chinaphar.com/article/view/8322